Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT05836753

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05836753
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05836753. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-07 (actual); primary completion 2023-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy
Acronym
ESPRIT
Condition
Ischemic Stroke, Acute
Intervention (Drug)
Sarecycline Tablet
Intervention (Drug)
Placebo tablets of Sarecycline tablets
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Neurodawn Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05836753
Content hash
863c60a1f37dd2314291191c8a361745b0be6a16c946ebaba6cc2978b139f6b0